Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

With its stock down 5.4% over the past month, it is easy to disregard Pfizer (NYSE:PFE). We, however decided to ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

The stock's dramatic 47% decline from its three-year high has created what I believe is a significant value opportunity. With a historically depressed forward P/E ratio of 8.7, Pfizer stock offers ...